Insider · CIK 0001702233
Catherine Stehman-Breen
director
Files at GBIO (Generation Bio Co.), DYN (Dyne Therapeutics, Inc.), TNYA (Tenaya Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 4, 2025 | GBIO Generation Bio Co. | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 6, 2025 |
| May 30, 2025 | DYN Dyne Therapeutics, Inc. | AGrant or award Stock option (right to buy)derivative | +35,000 | $0.00 | $0 | 35,000 | Jun 3, 2025 |
| May 29, 2025 | TNYA Tenaya Therapeutics, Inc. | AGrant or award Stock Option (Right to buy)derivative | +107,400 | $0.00 | $0 | 107,400 | May 30, 2025 |
| Oct 18, 2024 | TNYA Tenaya Therapeutics, Inc. | AGrant or award Stock Option (Right to buy)derivative | +34,000 | $0.00 | $0 | 34,000 | Oct 21, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.